Point of Care Diagnostics Market Size is projected to reach USD 66.37 billion by 2030, growing at a CAGR of 6.67%: Straits Research

The global point of care diagnostics market size was valued at USD 37.12 billion in 2021. It is projected to reach USD 66.37 billion by 2030, growing at a CAGR of 6.67% during the forecast period (2022–2030), The residential end-use market sector is anticipated to grow at a CAGR of 7.5% during the forecast period.

 | Source: Straits Research Straits Research

New York, United States, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Point-of-Care diagnostics are techniques used for the early and rapid diagnosis of disease. These techniques are susceptible and cost-effective and are applied in hospitals, clinics, ambulatory care, home healthcare, and research laboratories. The increasing prevalence of target illnesses is the most important factor driving market expansion. Point of care treatment permits speedy and dependable diagnostic testing with instantaneous results, enabling physicians/patients to make care-related decisions remotely and immediately.


Get a Free Sample Copy of This Report @ https://straitsresearch.com/report/point-of-care-diagnostics-market/request-sample


Increasing Value of Point of Care Diagnostics for Environmental Monitoring and Public Health and Proliferation of Infectious Diseases Drives the Global Market

The growing significance of point-of-care diagnostics in environmental monitoring and public health necessitates the development of technologies that simplify networking, making it more comfortable for medical practitioners to interpret test findings appropriately. Point-of-care tests can significantly improve the management of infectious diseases, especially in developing countries where timely access to healthcare can be challenging and when the healthcare system is underdeveloped and underfunded. In East and Southern Africa in 2021, UNAIDS estimated approximately 21.2 million HIV-positive individuals. Twenty thousand newly diagnosed cases of HIV were tallied throughout the Middle East and North Africa. It is anticipated that the demand for diagnostics that can be completed at the point of care will rise, accelerating the process of treating HIV infection.

Evolution of Remote Monitoring of Patients Creates Tremendous Opportunities

The application of digital technology is projected to substantially impact the creation of POC solutions in settings with limited resources. As part of their go-to-market strategy, businesses in the POCT sector should place the utmost importance on expanding their use of telehealth as the industry standard. It is anticipated that the emergence of remote patient monitoring systems such as PixCell Medical, point-of-care technology for CBC testing, would benefit the market's development.


Report Scope

Report Metric Details
Market Size by 2030 USD 66.37 billion
Market Size in 2021 USD 37.12 billion
CAGR 6.67% (2022-2030)
Historical Data 2019-2020
Base Year 2021
Forecast Period 2022-2030
Forecast Units Value (USD Billion)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered Product, End-User
Geographies Covered North America, Europe, Asia-Pacific, LAME and Rest of the World
Key Companies Profiled/Vendors F. Hoffmann-La Roche Ltd.; Qiagen; Danaher Corp.; Becton Dickinson (BD); Biomerieux SA; Abbott Laboratories; Siemens Healthcare AG; Zoetis, Inc.; Instrumentation Laboratory; Nova Biomedical; Trividia Health, Inc.; Quidel Corp.; Trinity Biotech; Sekisui Diagnostics; Orasure Technologies, Inc.; Nipro Corp.; Spectral Medical, Inc.
Key Market Opportunities Implementation of Remote Patient Monitoring
Key Market Drivers Growing Significance in Environmental Monitoring and Public Health
Rise of Infectious Diseases

Buy Now Full Report @ https://straitsresearch.com/buy-now/point-of-care-diagnostics-market 


Regional Analysis

North America maintained the largest revenue share in the global point of care diagnostics market due to the rapidly increasing number of COVID-19 cases and critical players in both the United States and Canada. For example, in March 2022, the company bioLytical Laboratories Inc., situated in Canada, was awarded CE marking for the iStatis COVID-19 Antigen Home Test.

Key Highlights

  • The global point of care diagnostics market size was valued at USD 37.12 billion in 2021. It is projected to reach USD 66.37 billion by 2030, growing at a CAGR of 6.67% during the forecast period (2022–2030).
  • Based on product, the market is divided into Glucose Testing, Hb1Ac Testing, Coagulation Testing, Fertility/Pregnancy, Infectious Disease, Cardiac Markers, Thyroid Stimulating Hormone, Hematology, Primary Care Systems, Decentralized Clinical Chemistry, Feces, Lipid Testing, Cancer Marker, Blood Gas/Electrolytes, Ambulatory Chemistry, Drug of Abuse (DOA) Testing, and Urinalysis/Nephrology. The infectious disorders segment owns a significant market share and is expected to grow during the forecast period.
  • Based on end-user, the market is segmented into clinics, hospitals, homes, assisted living healthcare facilities, and laboratories. The clinic segment is the most dominant in the global point of care diagnostics market, and pharmacy and retail clinics as the most significant contributors to this segment revenue.
  • North America maintained the largest revenue share in the global point of care diagnostics market.

Competitors in Point of Care Diagnostics Market

  • F. Hoffmann-La Roche Ltd
  • Qiagen
  • Danaher Corp.
  • Becton Dickinson (BD)
  • Biomerieux SA
  • Abbott Laboratories
  • Siemens Healthcare AG
  • Zoetis, Inc
  • Instrumentation Laboratory
  • Nova Biomedical
  • Trividia Health, Inc
  • Quidel Corp
  • Trinity Biotech
  • Sekisui Diagnostics
  • Orasure Technologies, Inc
  • Nipro Corp.
  • Spectral Medical, Inc


Get a Free Sample Copy of This Report @ https://straitsresearch.com/report/point-of-care-diagnostics-market/request-sample 


Segmentation of Point of Care Diagnostics Market

By Product

  • Glucose Testing
  • Hb1Ac Testing
  • Coagulation Testing
  • Fertility/Pregnancy
  • Infectious Disease
  • Cardiac Markers
  • Thyroid Stimulating Hormone
  • Hematology
  • Primary Care Systems
  • Decentralized Clinical Chemistry
  • Feces
  • Lipid Testing
  • Cancer Marker
  • Blood Gas/Electrolytes
  • Ambulatory Chemistry
  • Drug of Abuse (DOA) Testing
  • Urinalysis/Nephrology

By End-User

  • Clinics
  • Hospitals
  • Home
  • Assisted Living Healthcare Facilities
  • Laboratories

By Regions

  • North America
  • Europe
  • Asia-Pacific
  • LAMEA

TABLE OF CONTENT

  1. EXECUTIVE SUMMARY
  2. RESEARCH SCOPE & SEGMENTATION
    1. RESEARCH OBJECTIVES
    2. MARKET DEFINITION
    3. LIMITATIONS & ASSUMPTIONS
    4. MARKET SCOPE & SEGMENTATION
    5. CURRENCY & PRICING CONSIDERED
  3. MARKET OPPORTUNITY ASSESSMENT
    1. EMERGING REGIONS / COUNTRIES
    2. EMERGING COMPANIES
    3. EMERGING APPLICATIONS / END USE
    4. INVESTMENT LANDSCAPE
    5. NEW BUSINESS MODELS / REVENUE STREAMS
    6. TAM
  4. MARKET TRENDS
    1. DRIVERS
    2. MARKET WARNING FACTORS
    3. LATEST MACRO ECONOMIC INDICATORS
    4. GEOPOLITICAL IMPACT
    5. HUMAN FACTORS
    6. TECHNOLOGY FACTORS
  5. MARKET ASSESSMENT
    1. PORTERS FIVE FORCES ANALYSIS
    2. VALUE CHAIN ANALYSIS
    3. SALES AND DISTRIBUTION CHANNEL ANALYSIS
    4. TRADE ANALYSIS
    5. AVERAGE PRICING ANALYSIS
    6. PATENT ANALYSIS
    7. M & A AGREEMENTS & COLLABRATION ANALYSIS
    8. COST STRUCTURE ANALYSIS
  6. ESG TRENDS
  7. GLOBAL POINT OF CARE DIAGNOSTICS MARKET SIZE ANALYSIS
    1. GLOBAL POINT OF CARE DIAGNOSTICS MARKET INTRODUCTION
    2. BY PRODUCT
      1. INTRODUCTION
        1. PRODUCT BY VALUE
      2. GLUCOSE TESTING
        1. BY VALUE
      3. HB1AC TESTING
        1. BY VALUE
      4. COAGULATION TESTING
        1. BY VALUE
      5. FERTILITY/PREGNANCY
        1. BY VALUE
      6. INFECTIOUS DISEASE
        1. BY VALUE
      7. CARDIAC MARKERS
        1. BY VALUE
      8. THYROID STIMULATING HORMONE
        1. BY VALUE
      9. HEMATOLOGY
        1. BY VALUE
      10. PRIMARY CARE SYSTEMS
        1. BY VALUE
      11. DECENTRALIZED CLINICAL CHEMISTRY
        1. BY VALUE
      12. FECES
        1. BY VALUE
      13. LIPID TESTING
        1. BY VALUE
      14. CANCER MARKER
        1. BY VALUE
      15. BLOOD GAS/ELECTROLYTES
        1. BY VALUE
      16. AMBULATORY CHEMISTRY
        1. BY VALUE
      17. DRUG OF ABUSE (DOA) TESTING
        1. BY VALUE
      18. URINALYSIS/NEPHROLOGY
        1. BY VALUE
    3. BY END-USER
      1. INTRODUCTION
        1. END-USER BY VALUE
      2. CLINICS
        1. BY VALUE
      3. HOSPITALS
        1. BY VALUE
      4. HOME
        1. BY VALUE
      5. ASSISTED LIVING HEALTHCARE FACILITIES
        1. BY VALUE
      6. LABORATORIES
        1. BY VALUE
  8. NORTH AMERICA MARKET ANALYSIS
    1. INTRODUCTION
    2. BY PRODUCT
      1. INTRODUCTION
        1. PRODUCT BY VALUE
      2. GLUCOSE TESTING
        1. BY VALUE
      3. HB1AC TESTING
        1. BY VALUE
      4. COAGULATION TESTING
        1. BY VALUE
      5. FERTILITY/PREGNANCY
        1. BY VALUE
      6. INFECTIOUS DISEASE
        1. BY VALUE
      7. CARDIAC MARKERS
        1. BY VALUE
      8. THYROID STIMULATING HORMONE
        1. BY VALUE
      9. HEMATOLOGY
        1. BY VALUE
      10. PRIMARY CARE SYSTEMS
        1. BY VALUE
      11. DECENTRALIZED CLINICAL CHEMISTRY
        1. BY VALUE
      12. FECES
        1. BY VALUE
      13. LIPID TESTING
        1. BY VALUE
      14. CANCER MARKER
        1. BY VALUE
      15. BLOOD GAS/ELECTROLYTES
        1. BY VALUE
      16. AMBULATORY CHEMISTRY
        1. BY VALUE
      17. DRUG OF ABUSE (DOA) TESTING
        1. BY VALUE
      18. URINALYSIS/NEPHROLOGY
        1. BY VALUE
    3. BY END-USER
      1. INTRODUCTION
        1. END-USER BY VALUE
      2. CLINICS
        1. BY VALUE
      3. HOSPITALS
        1. BY VALUE
      4. HOME
        1. BY VALUE
      5. ASSISTED LIVING HEALTHCARE FACILITIES
        1. BY VALUE
      6. LABORATORIES
        1. BY VALUE
    4. U.S.
      1. BY PRODUCT
        1. INTRODUCTION
          1. PRODUCT BY VALUE
        2. GLUCOSE TESTING
          1. BY VALUE
        3. HB1AC TESTING
          1. BY VALUE
        4. COAGULATION TESTING
          1. BY VALUE
        5. FERTILITY/PREGNANCY
          1. BY VALUE
        6. INFECTIOUS DISEASE
          1. BY VALUE
        7. CARDIAC MARKERS
          1. BY VALUE
        8. THYROID STIMULATING HORMONE
          1. BY VALUE
        9. HEMATOLOGY
          1. BY VALUE
        10. PRIMARY CARE SYSTEMS
          1. BY VALUE
        11. DECENTRALIZED CLINICAL CHEMISTRY
          1. BY VALUE
        12. FECES
          1. BY VALUE
        13. LIPID TESTING
          1. BY VALUE
        14. CANCER MARKER
          1. BY VALUE
        15. BLOOD GAS/ELECTROLYTES
          1. BY VALUE
        16. AMBULATORY CHEMISTRY
          1. BY VALUE
        17. DRUG OF ABUSE (DOA) TESTING
          1. BY VALUE
        18. URINALYSIS/NEPHROLOGY
          1. BY VALUE
      2. BY END-USER
        1. INTRODUCTION
          1. END-USER BY VALUE
        2. CLINICS
          1. BY VALUE
        3. HOSPITALS
          1. BY VALUE
        4. HOME
          1. BY VALUE
        5. ASSISTED LIVING HEALTHCARE FACILITIES
          1. BY VALUE
        6. LABORATORIES
          1. BY VALUE
    5. CANADA
  9. EUROPE MARKET ANALYSIS
    1. INTRODUCTION
    2. BY PRODUCT
      1. INTRODUCTION
        1. PRODUCT BY VALUE
      2. GLUCOSE TESTING
        1. BY VALUE
      3. HB1AC TESTING
        1. BY VALUE
      4. COAGULATION TESTING
        1. BY VALUE
      5. FERTILITY/PREGNANCY
        1. BY VALUE
      6. INFECTIOUS DISEASE
        1. BY VALUE
      7. CARDIAC MARKERS
        1. BY VALUE
      8. THYROID STIMULATING HORMONE
        1. BY VALUE
      9. HEMATOLOGY
        1. BY VALUE
      10. PRIMARY CARE SYSTEMS
        1. BY VALUE
      11. DECENTRALIZED CLINICAL CHEMISTRY
        1. BY VALUE
      12. FECES
        1. BY VALUE
      13. LIPID TESTING
        1. BY VALUE
      14. CANCER MARKER
        1. BY VALUE
      15. BLOOD GAS/ELECTROLYTES
        1. BY VALUE
      16. AMBULATORY CHEMISTRY
        1. BY VALUE
      17. DRUG OF ABUSE (DOA) TESTING
        1. BY VALUE
      18. URINALYSIS/NEPHROLOGY
        1. BY VALUE
    3. BY END-USER
      1. INTRODUCTION
        1. END-USER BY VALUE
      2. CLINICS
        1. BY VALUE
      3. HOSPITALS
        1. BY VALUE
      4. HOME
        1. BY VALUE
      5. ASSISTED LIVING HEALTHCARE FACILITIES
        1. BY VALUE
      6. LABORATORIES
        1. BY VALUE
    4. U.K.
      1. BY PRODUCT
        1. INTRODUCTION
          1. PRODUCT BY VALUE
        2. GLUCOSE TESTING
          1. BY VALUE
        3. HB1AC TESTING
          1. BY VALUE
        4. COAGULATION TESTING
          1. BY VALUE
        5. FERTILITY/PREGNANCY
          1. BY VALUE
        6. INFECTIOUS DISEASE
          1. BY VALUE
        7. CARDIAC MARKERS
          1. BY VALUE
        8. THYROID STIMULATING HORMONE
          1. BY VALUE
        9. HEMATOLOGY
          1. BY VALUE
        10. PRIMARY CARE SYSTEMS
          1. BY VALUE
        11. DECENTRALIZED CLINICAL CHEMISTRY
          1. BY VALUE
        12. FECES
          1. BY VALUE
        13. LIPID TESTING
          1. BY VALUE
        14. CANCER MARKER
          1. BY VALUE
        15. BLOOD GAS/ELECTROLYTES
          1. BY VALUE
        16. AMBULATORY CHEMISTRY
          1. BY VALUE
        17. DRUG OF ABUSE (DOA) TESTING
          1. BY VALUE
        18. URINALYSIS/NEPHROLOGY
          1. BY VALUE
      2. BY END-USER
        1. INTRODUCTION
          1. END-USER BY VALUE
        2. CLINICS
          1. BY VALUE
        3. HOSPITALS
          1. BY VALUE
        4. HOME
          1. BY VALUE
        5. ASSISTED LIVING HEALTHCARE FACILITIES
          1. BY VALUE
        6. LABORATORIES
          1. BY VALUE
    5. GERMANY
    6. FRANCE
    7. SPAIN
    8. ITALY
    9. RUSSIA
    10. NORDIC
    11. BENELUX
    12. REST OF EUROPE
  10. APAC MARKET ANALYSIS
    1. INTRODUCTION
    2. BY PRODUCT
      1. INTRODUCTION
        1. PRODUCT BY VALUE
      2. GLUCOSE TESTING
        1. BY VALUE
      3. HB1AC TESTING
        1. BY VALUE
      4. COAGULATION TESTING
        1. BY VALUE
      5. FERTILITY/PREGNANCY
        1. BY VALUE
      6. INFECTIOUS DISEASE
        1. BY VALUE
      7. CARDIAC MARKERS
        1. BY VALUE
      8. THYROID STIMULATING HORMONE
        1. BY VALUE
      9. HEMATOLOGY
        1. BY VALUE
      10. PRIMARY CARE SYSTEMS
        1. BY VALUE
      11. DECENTRALIZED CLINICAL CHEMISTRY
        1. BY VALUE
      12. FECES
        1. BY VALUE
      13. LIPID TESTING
        1. BY VALUE
      14. CANCER MARKER
        1. BY VALUE
      15. BLOOD GAS/ELECTROLYTES
        1. BY VALUE
      16. AMBULATORY CHEMISTRY
        1. BY VALUE
      17. DRUG OF ABUSE (DOA) TESTING
        1. BY VALUE
      18. URINALYSIS/NEPHROLOGY
        1. BY VALUE
    3. BY END-USER
      1. INTRODUCTION
        1. END-USER BY VALUE
      2. CLINICS
        1. BY VALUE
      3. HOSPITALS
        1. BY VALUE
      4. HOME
        1. BY VALUE
      5. ASSISTED LIVING HEALTHCARE FACILITIES
        1. BY VALUE
      6. LABORATORIES
        1. BY VALUE
    4. CHINA
      1. BY PRODUCT
        1. INTRODUCTION
          1. PRODUCT BY VALUE
        2. GLUCOSE TESTING
          1. BY VALUE
        3. HB1AC TESTING
          1. BY VALUE
        4. COAGULATION TESTING
          1. BY VALUE
        5. FERTILITY/PREGNANCY
          1. BY VALUE
        6. INFECTIOUS DISEASE
          1. BY VALUE
        7. CARDIAC MARKERS
          1. BY VALUE
        8. THYROID STIMULATING HORMONE
          1. BY VALUE
        9. HEMATOLOGY
          1. BY VALUE
        10. PRIMARY CARE SYSTEMS
          1. BY VALUE
        11. DECENTRALIZED CLINICAL CHEMISTRY
          1. BY VALUE
        12. FECES
          1. BY VALUE
        13. LIPID TESTING
          1. BY VALUE
        14. CANCER MARKER
          1. BY VALUE
        15. BLOOD GAS/ELECTROLYTES
          1. BY VALUE
        16. AMBULATORY CHEMISTRY
          1. BY VALUE
        17. DRUG OF ABUSE (DOA) TESTING
          1. BY VALUE
        18. URINALYSIS/NEPHROLOGY
          1. BY VALUE
      2. BY END-USER
        1. INTRODUCTION
          1. END-USER BY VALUE
        2. CLINICS
          1. BY VALUE
        3. HOSPITALS
          1. BY VALUE
        4. HOME
          1. BY VALUE
        5. ASSISTED LIVING HEALTHCARE FACILITIES
          1. BY VALUE
        6. LABORATORIES
          1. BY VALUE
    5. KOREA
    6. JAPAN
    7. INDIA
    8. AUSTRALIA
    9. TAIWAN
    10. SOUTH EAST ASIA
    11. REST OF ASIA-PACIFIC
  11. MIDDLE EAST AND AFRICA MARKET ANALYSIS
    1. INTRODUCTION
    2. BY PRODUCT
      1. INTRODUCTION
        1. PRODUCT BY VALUE
      2. GLUCOSE TESTING
        1. BY VALUE
      3. HB1AC TESTING
        1. BY VALUE
      4. COAGULATION TESTING
        1. BY VALUE
      5. FERTILITY/PREGNANCY
        1. BY VALUE
      6. INFECTIOUS DISEASE
        1. BY VALUE
      7. CARDIAC MARKERS
        1. BY VALUE
      8. THYROID STIMULATING HORMONE
        1. BY VALUE
      9. HEMATOLOGY
        1. BY VALUE
      10. PRIMARY CARE SYSTEMS
        1. BY VALUE
      11. DECENTRALIZED CLINICAL CHEMISTRY
        1. BY VALUE
      12. FECES
        1. BY VALUE
      13. LIPID TESTING
        1. BY VALUE
      14. CANCER MARKER
        1. BY VALUE
      15. BLOOD GAS/ELECTROLYTES
        1. BY VALUE
      16. AMBULATORY CHEMISTRY
        1. BY VALUE
      17. DRUG OF ABUSE (DOA) TESTING
        1. BY VALUE
      18. URINALYSIS/NEPHROLOGY
        1. BY VALUE
    3. BY END-USER
      1. INTRODUCTION
        1. END-USER BY VALUE
      2. CLINICS
        1. BY VALUE
      3. HOSPITALS
        1. BY VALUE
      4. HOME
        1. BY VALUE
      5. ASSISTED LIVING HEALTHCARE FACILITIES
        1. BY VALUE
      6. LABORATORIES
        1. BY VALUE
    4. UAE
      1. BY PRODUCT
        1. INTRODUCTION
          1. PRODUCT BY VALUE
        2. GLUCOSE TESTING
          1. BY VALUE
        3. HB1AC TESTING
          1. BY VALUE
        4. COAGULATION TESTING
          1. BY VALUE
        5. FERTILITY/PREGNANCY
          1. BY VALUE
        6. INFECTIOUS DISEASE
          1. BY VALUE
        7. CARDIAC MARKERS
          1. BY VALUE
        8. THYROID STIMULATING HORMONE
          1. BY VALUE
        9. HEMATOLOGY
          1. BY VALUE
        10. PRIMARY CARE SYSTEMS
          1. BY VALUE
        11. DECENTRALIZED CLINICAL CHEMISTRY
          1. BY VALUE
        12. FECES
          1. BY VALUE
        13. LIPID TESTING
          1. BY VALUE
        14. CANCER MARKER
          1. BY VALUE
        15. BLOOD GAS/ELECTROLYTES
          1. BY VALUE
        16. AMBULATORY CHEMISTRY
          1. BY VALUE
        17. DRUG OF ABUSE (DOA) TESTING
          1. BY VALUE
        18. URINALYSIS/NEPHROLOGY
          1. BY VALUE
      2. BY END-USER
        1. INTRODUCTION
          1. END-USER BY VALUE
        2. CLINICS
          1. BY VALUE
        3. HOSPITALS
          1. BY VALUE
        4. HOME
          1. BY VALUE
        5. ASSISTED LIVING HEALTHCARE FACILITIES
          1. BY VALUE
        6. LABORATORIES
          1. BY VALUE
    5. TURKEY
    6. SAUDI ARABIA
    7. SOUTH AFRICA
    8. EGYPT
    9. NIGERIA
    10. REST OF MEA
  12. LATAM MARKET ANALYSIS
    1. INTRODUCTION
    2. BY PRODUCT
      1. INTRODUCTION
        1. PRODUCT BY VALUE
      2. GLUCOSE TESTING
        1. BY VALUE
      3. HB1AC TESTING
        1. BY VALUE
      4. COAGULATION TESTING
        1. BY VALUE
      5. FERTILITY/PREGNANCY
        1. BY VALUE
      6. INFECTIOUS DISEASE
        1. BY VALUE
      7. CARDIAC MARKERS
        1. BY VALUE
      8. THYROID STIMULATING HORMONE
        1. BY VALUE
      9. HEMATOLOGY
        1. BY VALUE
      10. PRIMARY CARE SYSTEMS
        1. BY VALUE
      11. DECENTRALIZED CLINICAL CHEMISTRY
        1. BY VALUE
      12. FECES
        1. BY VALUE
      13. LIPID TESTING
        1. BY VALUE
      14. CANCER MARKER
        1. BY VALUE
      15. BLOOD GAS/ELECTROLYTES
        1. BY VALUE
      16. AMBULATORY CHEMISTRY
        1. BY VALUE
      17. DRUG OF ABUSE (DOA) TESTING
        1. BY VALUE
      18. URINALYSIS/NEPHROLOGY
        1. BY VALUE
    3. BY END-USER
      1. INTRODUCTION
        1. END-USER BY VALUE
      2. CLINICS
        1. BY VALUE
      3. HOSPITALS
        1. BY VALUE
      4. HOME
        1. BY VALUE
      5. ASSISTED LIVING HEALTHCARE FACILITIES
        1. BY VALUE
      6. LABORATORIES
        1. BY VALUE
    4. BRAZIL
      1. BY PRODUCT
        1. INTRODUCTION
          1. PRODUCT BY VALUE
        2. GLUCOSE TESTING
          1. BY VALUE
        3. HB1AC TESTING
          1. BY VALUE
        4. COAGULATION TESTING
          1. BY VALUE
        5. FERTILITY/PREGNANCY
          1. BY VALUE
        6. INFECTIOUS DISEASE
          1. BY VALUE
        7. CARDIAC MARKERS
          1. BY VALUE
        8. THYROID STIMULATING HORMONE
          1. BY VALUE
        9. HEMATOLOGY
          1. BY VALUE
        10. PRIMARY CARE SYSTEMS
          1. BY VALUE
        11. DECENTRALIZED CLINICAL CHEMISTRY
          1. BY VALUE
        12. FECES
          1. BY VALUE
        13. LIPID TESTING
          1. BY VALUE
        14. CANCER MARKER
          1. BY VALUE
        15. BLOOD GAS/ELECTROLYTES
          1. BY VALUE
        16. AMBULATORY CHEMISTRY
          1. BY VALUE
        17. DRUG OF ABUSE (DOA) TESTING
          1. BY VALUE
        18. URINALYSIS/NEPHROLOGY
          1. BY VALUE
      2. BY END-USER
        1. INTRODUCTION
          1. END-USER BY VALUE
        2. CLINICS
          1. BY VALUE
        3. HOSPITALS
          1. BY VALUE
        4. HOME
          1. BY VALUE
        5. ASSISTED LIVING HEALTHCARE FACILITIES
          1. BY VALUE
        6. LABORATORIES
          1. BY VALUE
    5. MEXICO
    6. ARGENTINA
    7. CHILE
    8. COLOMBIA
    9. REST OF LATAM
  13. COMPETITIVE ASSESSMENT
    1. ADOPTION MATRIX
    2. POINT OF CARE DIAGNOSTICS MARKET SHARE BY MANUFACTURERS
    3. POINT OF CARE DIAGNOSTICS MARKET RANKING BY REVENUE FOR MANUFACTURERS
    4. AVERAGE PRICE BY MANUFACTURERS
    5. VENDOR FOOTPRINT ANALYSIS
  14. MARKET PLAYERS ASSESSMENT
    1. HOFFMANN-LA ROCHE LTD.
      1. OVERVIEW
      2. BUSINESS INFORMATION
      3. REVENUE
      4. ASP
      5. GROSS MARGIN
      6. SWOT ANALYSIS
      7. RECENT DEVELOPMMENTS
    2. QIAGEN
    3. DANAHER CORP.
    4. BECTON DICKINSON (BD)
    5. BIOMERIEUX SA
    6. ABBOTT LABORATORIES
    7. SIEMENS HEALTHCARE AG
    8. ZOETIS INC.
    9. INSTRUMENTATION LABORATORY
    10. NOVA BIOMEDICAL
    11. TRIVIDIA HEALTH INC.
    12. QUIDEL CORP.
    13. TRINITY BIOTECH
    14. SEKISUI DIAGNOSTICS
    15. ORASURE TECHNOLOGIES INC.
    16. NIPRO CORP.
    17. SPECTRAL MEDICAL INC
  15. RESEARCH METHODOLOGY
    1. RESEARCH DATA
      1. SECONDARY DATA
        1. MAJOR SECONDARY SOURCES
        2. KEY DATA FROM SECONDARY SOURCES
      2. PRIMARY DATA
        1. KEY DATA FROM PRIMARY SOURCES
        2. BREAKDOWN OF PRIMARIES
      3. SECONDARY AND PRIMARY RESEARCH
        1. KEY INDUSTRY INSIGHTS
    2. MARKET SIZE ESTIMATION
      1. BOTTOM-UP APPROACH
      2. TOP-DOWN APPROACH
      3. MARKET PROJECTION
    3. RESEARCH ASSUMPTIONS
      1. ASSUMPTIONS
    4. LIMITATIONS
    5. RISK ASSESSMENT
  16. APPENDIX
    1. DISCUSSION GUIDE
    2. CUSTOMIZATION OPTIONS
    3. RELATED REPORTS
  17. DISCLAIMER


Table of Content and Figure @ https://straitsresearch.com/report/point-of-care-diagnostics-market/toc


Recent Development

  • June 2022- Roche launches the VENTANA DP 600 slide scanner for digital pathology, enhancing patient care with precision diagnostics.
  • June 2022- Roche launches human papillomavirus (HPV) self-sampling solution, expanding cervical cancer screening options.
  • May 2022- QIAGEN launches therascreen EGFR Plus RGQ PCR Kit featuring C797S detection to help guide non-small cell lung cancer (NSCLC) treatment.
  • June 2022- BD Collaborates with Mayo Clinic Platform, Leveraging Real-World Clinical Data to Improve Post-Market Device Surveillance, Drive Innovation for Patient Care.


News Media

Global Veterinary Point of Care Diagnostics Market to Grow at a CAGR of 10.45% During 2020 –2030

Global Point of Care Diagnostics Market Grows Steadily at a CAGR of 6.67%


Have a Look at the Related Research Report

Veterinary Point of Care Diagnostics Market: Information by Animal Type (Companion, Livestock), Product (Consumables, Reagents), Sample Type (Urine, Fecal), and Regions—Forecast Till 2030

Ambulatory Surgery Center Market: Information by Products & Services (Clinical It Solutions, Non-Clinical Healthcare It Solutions), Components (Services), and Region — Forecast till 2030

Smart Home Healthcare Market: Information by Aging-in-Place (Perspective of Aging in Smart Homes), General Health and Wellness (Concept of General Health), and Region—Forecast Till 2031

Home Healthcare Devices Market: Information By Product (BP & Heart Rate Monitor, Ovulation Kit, Pedometer, Cane, wheelchair), Software, Services, and Regional Outlook - Forecast Till 2030

Veterinary Infectious Disease Diagnostics Market: Information by Product (Immunodiagnostics, Molecular Diagnostics), Application (Dogs, Cats), and Regions—Forecast Till 2031


About Straits Research Pvt. Ltd.

Straits Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision making and ROI.

Whether you are looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with the client’s purchase. We overcome our clients’ issues by recognizing and deciphering the target group and generating leads with utmost precision. We seek to collaborate with our clients to deliver a broad spectrum of results through a blend of market and business research approaches.


For more information on your target market, please contact us below:

Phone: +1 646 480 7505 (the U.S.)

+91 8087085354 (APAC)

+44 208 068 9665 (the U.K.)

Email: sales@straitsresearch.com

Follow Us: LinkedIn | Facebook | Instagram | Twitter


Tags

Point of Care (POC)Diagnostics POC testing POC Diagnostics Market Size POCT devices POC diagnostic applications healthcare USA

Related Links